ENCell Co., Ltd., a South Korean biotech leader specializing in Cell and Gene Therapy (CGT), has unveiled promising results from their first-in-human Phase 1 clinical trial of EN001, a novel mesenchymal stem cell therapy aimed at treating Charcot-Marie-Tooth disease type 1A (CMT1A). The findings were presented at the Peripheral Nerve Society (PNS) annual meeting held […]
Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), renowned for its innovative therapies in cellular metabolism and pyruvate kinase (PK) activation, has announced promising results from its global Phase 3 ENERGIZE-T study. The study focused on mitapivat, a novel treatment for adults with transfusion-dependent alpha- or beta-thalassemia, achieving its primary endpoint of significant transfusion reduction, along with all […]
Novartis presented compelling interim results from the Phase III ALIGN study evaluating the efficacy of atrasentan, an investigational oral selective endothelin A (ETA) receptor antagonist, in patients with IgA nephropathy (IgAN). This data was highlighted at the European Renal Association (ERA) Congress, showcasing a significant 36.1% reduction in proteinuria at 36 weeks compared to placebo, […]
Zealand Pharma A/S (Nasdaq: ZEAL), a pioneer in peptide-based drug development, has shared topline results from its DREAM trial, evaluating the efficacy of low doses of the GLP-1/GLP-2 receptor dual agonist, dapiglutide, in treating obesity. This clinical study marks a significant step forward in understanding the potential of dapiglutide to induce weight loss without lifestyle […]
Eupraxia Pharmaceuticals Inc., listed on both TSX and NASDAQ under the ticker EPRX, has revealed encouraging results from its ongoing Phase 1b/2a RESOLVE trial. The trial is evaluating EP-104GI, a new treatment for eosinophilic esophagitis (EoE), utilizing the company’s proprietary DiffuSphere technology. Trial Results Show Efficacy and Safety The latest data from the RESOLVE trial’s […]
Roche has announced positive outcomes from the Phase I clinical trial of CT-388, a novel dual GLP-1/GIP receptor agonist, which is being developed as a once-weekly subcutaneous injection for the treatment of obesity and type 2 diabetes. The trial results revealed significant weight loss and improved glycemic control in participants, positioning CT-388 as a potentially […]
Lyra Therapeutics, Inc. (Nasdaq: LYRA), dedicated to advancing treatments for chronic rhinosinusitis (CRS), announced that its Phase 3 ENLIGHTEN 1 trial evaluating LYR-210 did not meet its primary endpoint. The trial aimed to demonstrate a statistically significant improvement over a sham control in treating CRS symptoms, but the results at 24 weeks fell short of […]
Regeneron Pharmaceuticals and Sanofi have received a significant boost with the European Commission’s (EC) approval of Praluent (alirocumab) for a new indication. The approval enables Praluent to be used as an adjunct treatment to reduce low-density lipoprotein cholesterol (LDL-C) levels in adults with atherosclerotic cardiovascular disease (ASCVD), aiming to lower the risk of further cardiovascular […]
In a significant development, Astellas Pharma and Pfizer have announced that the U.S. Food and Drug Administration (FDA) has expanded the approval of their cancer drug Xtandi (enzalutamide) for the treatment of men with non-metastatic castration-resistant prostate cancer (CRPC). This marks an important step forward in the treatment options available to patients suffering from this […]